Tempus AI is a precision medicine company that uses AI to analyze genomic sequencing, clinical data, and imaging to improve cancer diagnosis and treatment decisions. Its sequencing services generate detailed genomic profiles of tumors, while AI models correlate those profiles with treatment outcomes and drug response data from the largest real-world clinical database in oncology. Oncologists, cancer researchers, and genomic medicine teams use Tempus to identify the most effective treatments for specific cancer presentations based on their genetic profile and clinical characteristics. The AI analyzes patterns across the company's database of genomic and clinical data to surface treatment recommendations that may not be apparent from population-level clinical trial data alone. Tempus IPO'd in June 2024 at a valuation reflecting its position as a leader in AI-driven oncology. Its combination of sequencing services, AI analytics, and real-world data network creates a compounding advantage as more clinical data flows through the platform. The breadth of data for oncology AI -- over 220,000 sequenced patients -- is unmatched in the industry.

What the community says

Tempus AI is highly regarded in oncology and precision medicine communities for the breadth of its genomic database and the clinical evidence behind its AI recommendations. Oncologists cite it as providing meaningful insights for complex cases where standard treatment guidelines don't account for specific genomic profiles. Based on community discussions from oncology publications and LinkedIn.